Clinical Trials Logo
  1. Home
  2. Paranasal Sinus Cancer
  3. NCT05114707

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Induction Chemotherapy Clinical Trial

Official title:
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses: a Phase II Multicenter Study

Clinical Trial Summary

Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05114707
Study type Interventional
Source Sun Yat-sen University
Contact Fei Han
Phone +86 13822113698
Email hanfei@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date April 16, 2021
Completion date April 16, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04539600 - Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer Phase 2
Recruiting NCT05397769 - Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. Phase 2
Completed NCT04473716 - Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Phase 1
Recruiting NCT06093438 - Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT04446130 - Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients Phase 3
Recruiting NCT02924909 - Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer Phase 2
Active, not recruiting NCT04384627 - Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Phase 3
Recruiting NCT04087967 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients Phase 3
Recruiting NCT04083911 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 Phase 3